Importantly, genetic ablation of Rspo1 robustly increases the thermogenic capacity of visceral fat and resists HFD‐induced obesity in vivo, indicating the underlying therapeutic potential to treat obesity by blocking RSPO1 signaling in adipose tissues (Figure S10C, Supporting Information). This evidence concerns the gene RSPO1 and obesity due to melanocortin 4 receptor deficiency.